Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228883 | 0.92 | ADORA1 (0.40) | ADORA1ADORA3ADORA2AGPR183VCP | |
| SCHEMBL3228751 | 0.86 | VCP (0.47) | ADORA1ADORA3ADORA2AVCPAKT1 | |
| SCHEMBL3228889 | 0.84 | ADORA1 (0.39) | ADORA1ADORA3ADORA2AGPR183VCP | |
| SCHEMBL3227596 | 0.83 | AKT1 (0.42) | ADORA1ADORA3ADORA2AVCPAKT1 | |
| SCHEMBL3236168 | 0.82 | AKT1 (0.40) | ADORA1ADORA3ADORA2AVCPAKT1 | |
| SCHEMBL3229585 | 0.80 | SYK (0.40) | ADORA1ADORA3VCPAKT1SYK | |
| SCHEMBL3228961 | 0.80 | MAPT (0.47) | VCPAKT1SYKMAPT | |
| SCHEMBL13456904 | 0.79 | VCP (0.48) | VCP | |
| SCHEMBL13456945 | 0.79 | AKT1 (0.39) | ADORA1ADORA3ADORA2AVCPAKT1 | |
| SCHEMBL3268108 | 0.79 | MAPT (0.43) | ADORA1ADORA3VCPAKT1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | ADORA1 2916/4885ADORA3 3583/4885ADORA2A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.